![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/redhill-announces-a-new-patent-covering-opaganib-in-combination-with-immune-checkpoint-inhibitors-valid-through-2040-302161731.html
https://www.prnewswire.com/news-releases/redhill-announces-new-opaganib-chinese-patent-against-ebola-virus-valid-through-2035-302136648.html
https://www.prnewswire.com/news-releases/redhill-announces-first-patient-enrolled-in-us-government-supported-covid-19-study-302126003.html
https://www.prnewswire.com/news-releases/redhill-biopharma-announces-full-year-2023-results-and-operational-highlights-302110455.html
https://www.prnewswire.com/news-releases/redhill-biopharma-announces-1-25-million-registered-direct-offering-at-a-premium-to-market-price-302105607.html
https://www.prnewswire.com/news-releases/redhill-announces-new-uspto-patent-covering-talicia-through-2034-302085225.html
https://www.prnewswire.com/news-releases/redhills-opaganib-selected-for-evaluation-by-barda-and-nih-countermeasures-programs-302079686.html
https://www.prnewswire.com/news-releases/redhills-opaganib-protects-against-radiation-induced-lung-inflammation-and-fibrosis--new-publication-302065891.html
https://www.prnewswire.com/news-releases/redhill-biopharma-announces-closing-of-8-million-registered-direct-offering-302045836.html
https://www.prnewswire.com/news-releases/redhill-biopharma-announces-8-million-registered-direct-offering-302044755.html